Nefrología e hipertensión

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Authorizaton to Use Clincially Obtained Data for Research

   Rochester, Minn.

   This study is being done to gather information regarding your health in relation to your composite tissue transplant. We would like to use your medical records (both existing and future) to study the health of patients who will receive or have received a composite tissue transplant. This research would include looking at your demographic information, cause of initial injury, laboratory test results and medical exams relating to your pre and post transplant care, and your mental well-being before and after transplant.

    

2. Avacopan in Crescentic IgAN

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic IgAN and high risk of progression.

3. Biobank Protocol, Rare Diseases Clinical Research Network

   Rochester, Minn.

   This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

4. OBINUTUZUMAB in Treatment of Fibrillary Glomerulonephritis

   Rochester, Minn.

   The purpose of this study is to determine if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.

5. A Study of Genes that cause Cystic Kidney Disease

   Rochester, Minn.

   The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods.  A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.

6. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with  monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.

   Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and cytopenias.

7. A Study to Form a Database of Children with Kidney Stone Disease

   Rochester, Minn.

   The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

8. Obstructive Sleep Apnea Among Somali-Americans

   Rochester, Minn.

   The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent.

9. A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

   Rochester, Minn.

   Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

10. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

    Rochester, Minn.

    The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

     

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

    

2. Avacopan in Crescentic IgAN

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic IgAN and high risk of progression.

3. Biobank Protocol, Rare Diseases Clinical Research Network

   Rochester, Minn.

   This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

4. OBINUTUZUMAB in Treatment of Fibrillary Glomerulonephritis

   Rochester, Minn.

   The purpose of this study is to determine if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.

5. A Study of Genes that cause Cystic Kidney Disease

   Rochester, Minn.

   The overall objective of this study is to define genes causing cystic kidney disease and to determine the degree to which variants at these cystic kidney disease genes underlie the clinical diversity of these disorders. This will provide an insight into the disease mechanisms, and explore novel mutation screening methods.  A combination of mutation screening in clinically characterized human cystic kidney disease populations, gene hunting and exploration of incompletely penetrant alleles in humans will provide a comprehensive picture of how mutations cause the resulting phenotype.

6. Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with  monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.

   Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and cytopenias.

7. A Study to Form a Database of Children with Kidney Stone Disease

   Rochester, Minn.

   The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

8. Obstructive Sleep Apnea Among Somali-Americans

   Rochester, Minn.

   The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent.

9. A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

   Rochester, Minn.

   Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

10. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

    Rochester, Minn.

    The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).